First prospective study of its kind conducted in primary care settings, shows remarkable diagnostic performance: 95% sensitivity and 86% specificity,...
Northern CapSek Ventures takes part in oversubscribed round First prospective clinical trials showing unmatched levels of sensitivity and specificity Funds...
Clinical study in Swedish primary care facilities to validate Dermalyser AI-driven decision support tool for diagnosing malignant melanoma progressing well...
AI Medical Technology reports highly promising results from clinical study in primary care facilities to validate Dermalyser – an AI-driven support tool for diagnosing melanoma skin cancer
AI Medical Technology nets SEK10.8 million to accelerate Dermalyser AI-driven diagnostic support tool for skin cancer
AI Medical Technology Featured in MedTech Strategist
AI Medical Technology Receives ISO 13485:2016 Certification
Clinical Study Initiated in Primary Care Facilities to Validate Dermalyser